检索结果-南通市图书馆

daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

World Journal of Gastroenterology 2016年第12期22卷 3418-3431页

作者： Ira Jacobson Stefan Zeuzem Robert Flisiak Brygida Knysz Stefan Lueth Dorota Zarebska-Michaluk Ewa Janczewska Peter Ferenci Moises Diago Anna Linda Zignego Rifaat Safadi Yaacov Baruch Dzhamal Abdurakhmanov Stephen Shafran Dominique Thabut Rafael Bruck Adrian Gadano Alexander James Thompson Justin Kopit Fiona Mc Phee Tracy Michener Eric A Hughes Philip D Yin Stephanie Noviello Weill Cornell Medical College New YorkNY 10029United States Icahn School of Medicine at Mount Sinai New YorkNY 10029United States JW Goethe University Hospital 60323 FrankfurtGermany Uniwersytet Medyczny w Bialymstoku 15-089 BialystokPoland EMC and Medical University 50-220 WroclawPoland Universitatsklinikum Hamburg-Eppendorf 20246 HamburgGermany Wojewodzki Szpital Zespolony w Kielcach 25-736 KielcePoland ID Clinic 41-400 MyslowicePoland Medizinische Universitat Wien 1090 ViennaAustria Clinica Quiron 46010 ValenciaSpain Universita degli Studi di Firenze 50121 FlorenceItaly Holy Family Hospital Nazareth 6004Israel Rambam Medical Center Haifa 31096Israel 1st Moscow State Medical University N.A.I.M.Sechenov 119991 MoscowRussia University of Alberta Hospital EdmontonAlberta T6G 2B7Canada Groupe Hospitalier Pitie-Salpetriere 75013 ParisFrance Tel Aviv Sourasky Medical Center and Tel Aviv University Tel Aviv 64239Israel Hospital Italiano de Buenos Aires Buenos Aires C1181ACHArgentina St.Vincents Hospital and the University of Melbourne Melbourne 3065Australia Fiona McPhee Bristol-Myers Squibb Research and DevelopmentWallingfordCT 06492United States Bristol-Myers Squibb Research and Development PrincetonNJ 08450United States

AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin(peg IFN/RBV), in treatment-naive hepatitis C virus(HCV) genotype(GT) 1-infected ***: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned(2:1) to daclatasvir vs telaprevir, stratified by IL28 B rs12979860 host genotype(CC vs non-CC), cirrhosis status(compensated cirrhosis vs no cirrhosis), and HCV GT1 subtype(GT1a vs GT1b). Patients were selected by study inclusion criteria from a total of 793 enrolled patients. Patients received daclatasvir 60 mg once daily or telaprevir 750 mg 3 times daily plus peg IFN/RBV. daclatasvir recipients received 24 wk of daclatasvir plus peg IFN/RBV; those without an extended rapid virologic response(e RVR; undetectable HCV-RNA at weeks 4 and 12) received an additional 24 wk of peg IFN/RBV. Telaprevir-treated patients received 12 wk of telaprevir plus peg IFN/RBV followed by 12(with e RVR) or 36(no e RVR) wk of peg IFN/RBV. The primary objective was to compare for noninferiority of sustained virologic response rates at posttreatment week 12(SVR12) in GT1b-infected patients. Key secondary objectives were to demonstrate that the rates of anemia(hemoglobin daclatasvir + peg IFN/RBV than with telaprevir + peg IFN/RBV among GT1b-infected patients. Resistance testing was performed using population-based sequencing of the NS5 A region for all patients at baseline, and for patients with virologic failure or relapse and HCV-RNA ≥ 1000 IU/m L, to investigate any link between NS5 A polymorphisms associated with daclatasvir resistance and virologic outcome. RESULTS: Patient demographics and disease characteristics were generally balanced across treatment arms; however, there was a higher proportion of black/African Americans in the daclatasvir groups(6.0% and 8.2% in the GT1 b and GT1 a groups, respectively) than in the telaprevi

关键词： Direct-acting antiviral Chronic hepatitis C daclatasvir Genotype 1b NS5A inhibitor Liver disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

daclatasvir plus asunaprevir in treatment-na?ve patients with hepatitis C virus genotype 1b infection

引用

World Journal of Gastroenterology 2018年第12期24卷 1361-1372页

作者： Lai Wei Fu-Sheng Wang Ming-Xiang Zhang Ji-Dong Jia Alexey A Yakovlev Wen Xie Eduard Burnevich Jun-Qi Niu Yong Jin Jung Xiang-Jun Jiang Min Xu Xin-Yue Chen Qing Xie Jun Li Jin-Lin Hou Hong Tang Xiao-guang Dou Yash Gandhi Wen-Hua Hu Fiona McPhee Stephanie Noviello Michelle Treitel Ling Mo Jun Deng Peking University People’s Hospital and Peking University Hepatology Institute Beijing 100044China Qingdao Municipal Hospital Qingdao 266011Shandong ProvinceChina Guangzhou No.8 People’s Hospital Guangzhou 510060Guangdong ProvinceChina Beijing Youan Hospital Capital Medical UniversityBeijing 100069China Shanghai Ruijin Hospital Jiaotong University School of MedicineShenyang 200025Liaoning ProvinceChina TheFirst Affiliated Hospital with Nanjing Medical University Nanjing 210029Jiangsu ProvinceChina Hepatology Unit Nanfang HospitalSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina West China Hospital Sichuan UniversityChengdu 610041Sichuan ProvinceChina China Medical University Shengjing HospitalShenyang 110004Liaoning ProvinceChina Bristol-Myers Squibb PrincetonNJ 08540United States Bristol-Myers Squibb WallingfordCT 06492United States 302 Military Hospital of China Beijing 100039China Bristol-Myers Squibb Shanghai 200040China the Sixth People’s Hospital of Shenyang Shenyang 110006Liaoning ProvinceChina Beijing Friendship Hospital Capital Medical UniversityBeijing 100050China Saint-Petersburg State Healthcare Institution'Clinical Infectious Hospital n.a.S.P.Botkin’ Saint-Petersburg 191167Russia Beijing Ditan Hospital Capital Medical UniversityBeijing 100015China I.M.Sechenov First Moscow State Medical University Moscow 119991Russia The First Hospital of Jilin University Jilin 1300021Jilin ProvinceChina SMG-SNU Boramae Medical Center Seoul 07061South Korea

AIM To assess daclatasvir plus asunaprevir(d UAL) in treatment-na?ve patients from China's Mainland, Russia and South Korea with hepatitis C virus(HCV) genotype 1 b infection. METHODS Patients were randomly assigned(3:1) to receive 24 wk of treatment with d UAL(daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily) beginning on day 1 of the treatment period(immediate treatment arm) or following 12 wk of matching placebo(placebodeferred treatment arm). The primary endpoint was a comparison of sustained virologic response at posttreatment week 12(SVR12) compared with the historical SVR rate for peg-interferon plus ribavirin(70%) among patients in the immediate treatment arm. The first 12 wk of the study were blinded. Safety was assessed in d UAL-treated patients compared with placebo patients during the first 12 wk(doubleblind phase), and during 24 wk of d UAL in both arms *** In total, 207 patients were randomly assigned to immediate(n = 155) or placebo-deferred(n = 52) treatment. Most patients were Asian(86%), female(59%) and aged < 65 years(90%). Among them, 13% had cirrhosis, 32% had IL28 B non-CC genotypes and 53% had baseline HCV RNA levels of ≥ 6 million IU/m L. Among patients in the immediate treatment arm, SVR12 was achieved by 92%(95% confidence interval: 87.2-96.0), which was significantly higher than the historical comparator rate(70%). SVR12 was largely unaffected by cirrhosis(89%), age ≥ 65 years(92%), male sex(90%), baseline HCV RNA ≥ 6 million(89%) or IL28 B non-CC genotypes(96%), although SVR12 was higher among patients without(96%) than among those with(53%) baseline NS5 A resistanceassociated polymorphisms(at L31 or Y93 H). during the double-blind phase, aminotransferase elevations were more common among placebo recipients than among patients receiving d UAL. during 24 wk of d UAL therapy(combined arms), the most common adverse events(≥ 10%) were elevated alanine aminotransferase and upper respiratory tract infection; emergent

关键词： Asunaprevir daclatasvir Direct-acting antiviral Chronic hepatitis C Liver disease NS3 NS5A Genotype 1b

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions

引用

World Journal of Hepatology 2017年第25期9卷 1064-1072页

作者： Hideki Fujii Atsushi Umemura Taichiro Nishikawa Kanji Yamaguchi Michihisa Moriguchi Hideki Nakamura Kohichiroh Yasui Masahito Minami Saiyu Tanaka Hiroki Ishikawa Hiroyuki Kimura Shiro Takami Yasuyuki Nagao Toshihide Shima Yoshito Itoh Department of Molecular Gastroenterology and Hepatology Kyoto Prefectural University of Medicine Department of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Department of Gastroenterology and Hepatology North Medical CenterKyoto Prefectural University of Medicine Department of Internal Medicine Aiseikai Yamashina Hospital Center for Digestive and Liver Diseases Nara City Hospital Department of Gastroenterology and Hepatology Omihachiman Community Medical Center Department of Gastroenterology Otsu Municipal Hospital Department of Gastroenterology Matsushita Memorial Hospital Center of Gastroenterology and Hepatology Saiseikai Suita Hospital

AIM To investigate daclatasvir(DCV) and asunaprevir(ASV) efficacy in hepatitis C(HCV) patients, with respect to resistance-associated substitutions(RASs).METHODS A total of 392 HCV-infected patients from multiple centers were included in this study. We evaluated their clinical courses and sustained virologic responses(SVR) according to pretreatment factors(gender, age, history of interferon-based regimens, platelet counts, level of viremia, pretreatment NA5A:L31, and Y93 substitutions). We also analyzed the pretreatment and post-treatment major RASs of NS3:D168, NS5A:L31 and Y93 substitutions using a direct-sequencing method in 17 patients who were unable to achieve SVR at 12 wk after treatment completion(SVR12).RESULTS The overall SVR12 rate was 88.3%. Thirty-one patients discontinued treatment before 24 wk because of adverse events, 23 of whom achieved SVR12. There were no significant differences in SVR12 rates with respect to gender, age, history of interferon-based regimens, and platelet counts. The SVR12 rate in patients with viral loads of ≥ 6.0 log IU/m L was significantly lower than those with viral loads of < 6.0 log IU/m L(P < 0.001). The SVR12 rate in patients with Y93 substitution-positive was significantly lower than those with Y93 substitution-negative(P < 0.001). The L31 substitution-positive group showed a lower SVR12 rate than the L31 substitution-negative group, but the difference was not statistically significant. Seventeen patients who did not achieve SVR12 and had available pretreatment and post-treatment sera had additional RASs in NS3:D168, NS5:L31, and Y93 substitution at treatment *** Combination of DCV and ASV is associated with a high SVR rate. Baseline RASs should be thoroughly assessed to avoid additional RASs after treatment failure.

关键词： Hepatitis C Asunaprevir Combination therapy Resistance-associated substitutions daclatasvir

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus

引用

World Journal of Clinical Cases 2016年第3期4卷 88-93页

作者： Ken Sato Yuichi Yamazaki Tatsuya Ohyama Takeshi Kobayashi Norio Horiguchi Satoru Kakizaki Motoyasu Kusano Masanobu Yamada Department of Medicine and Molecular Science Gunma University Graduate School of Medicine Department of Gastroenterology Heisei Hidaka Clinic Department of Endoscopy and Endoscopic Surgery Gunma University Hospital

The standard antiviral therapy for dialysis patients infected with hepatitis C virus(HCV) is(pegylated) interferon monotherapy, but its efficacy is insufficient. Oral direct-acting antiviral agents(DAAs) have recently been developed for chronic hepatitis C patients. However, some DAAs have contraindications for chronic renal failure(CRF). daclatasvir and asunaprevir are metabolized largely in the liver and are not contraindicated in CRF. Combination therapy with daclatasvir and asunaprevir was used for 4 dialysis patients infected with genotype 1b HCV. One patient had viral breakthrough, and the 3 others had sustained virological response 12. One patient was admitted for heart failure and percutaneous coronary intervention due to concomitant ischemic disease. Heart failure was unlikely to be caused by the combination therapy, as it was probably due to water overload. The patient continued to receive the combination therapy after the remission of the heart failure. The combination therapy was well tolerated in the other patients.

关键词： Hepatitis C Oral drug daclatasvir Asunaprevir Dialysis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection

引用

World Journal of Gastroenterology 2017年第32期23卷 5969-5976页

作者： Yan Xue Li-Xin Zhang Lei Wang Tao Li Yun-Dong Qu Feng Liu Department of Infectious Diseases and Hepatology the Second Hospital of Shandong University

AIM To assess the efficacy and safety of sofosbuvir and daclatasvir regimens for kidney transplantation(KT) patients with hepatitis C virus(HCV) *** This study enrolled a prospective cohort of consecutive Chinese KT patients with HCV infection. They were given sofosbuvir combined with daclatasvir, with or without ribavirin. They were monitored regularly during and after the treatment. RESULTS Six patients were recruited in our prospective study cohort. All patients were male and naive to directacting antiviral treatment. The treatment duration was 12 wk. Most patients(4/6) were infected with HCV genotype 1b. HCV RNA was undetectable at week 4 after treatment and at the end of treatment in all patients. Sustained virological response rate at 12 wk was 100%(6/6). Two patients had to accept a half dose of sofosbuvir due to serum creatinine elevation during treatment. Kidney function in the remaining patients was stable. No serious adverse events(AEs) were observed. No patient discontinued antiviral therapy due to side effects. CONCLUSION Sofosbuvir and daclatasvir for treatment of KT recipients with HCV infection are highly efficient and safe. Patients tolerated the medications well, and no serious AEs were observed. Larger prospective cohort studies are needed to validate these results.

关键词： Hepatitis C virus Sofosbuvir daclatasvir Kidney transplantation Direct-acting antivirals

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy

引用

World Journal of Clinical Cases 2019年第16期7卷 2247-2255页

作者： Mortada HF El-Shabrawi Laila M Sherief Mostafa Yakoot Naglaa M Kamal Mohamed A Almalky Manal M AbdElgawad Aml A Mahfouz Sherine Helmy Enas M Kamal Dina Attia Hisham R El-Khayat Paediatric Hepatology Department Cairo Faculty of MedicineCairo 11559Egypt Paediatric Hematology-Oncology Department Zagazig Faculty of MedicineZagazig 21121Egypt Internal medicine Pediatrics and HepatologyGreen Clinic and Research CenterAlexandria UniversityAlexandria 21121Egypt Paediatric Hepatology Department Alexandria Faculty of medicineAlexandria 21121Egypt Innovations & Research Pharco CorporationAlexandria 21121Egypt Endemic medicine and Hepatology Department Minia UniversityMinia 22233Egypt Endemic medicine and Hepatology Department Beni-suef UniversityBeni-suef 62511Egypt Gastroenterology and Endemic Medicine Department Theodore Research InstituteCairo 23323Egypt

BACKGROUND Childhood cancer survivors are potentially at a higher risk of infection with hepatitis C virus (HCV).The effects of all-oral direct-acting antiviral therapy (DAA) on both the HCV infection as well as the state of cancer remission have not been well investigated in this *** To test the effects of dual sofosbuvir/daclatasvir (SOF/DCV) therapy in the treatment of chronic HCV in survivors of hematologic malignancy in pediatric age *** We conducted a prospective,uncontrolled,open-label multicenter study.A total of 20 eligible,chronic HCV,genotype-4,infected children who had been in continuous complete remission from hematologic cancer (leukemia/lymphoma) for at least one year were included in the *** patients were treated with combined SOF/DCV for 12 *** were monitored throughout the study till 12 wk after end of treatment for safety and efficacy outcomes including the sustained virologic response 12 (SVR12) rate,hematological indices,liver and kidney *** The intent-to-treat SVR12 rate was 20 of 20 (100%;95%CI: 84%-100%).All patients showed normalized liver enzymes from *** hematological indices,liver and kidney functions were kept normal throughout the *** fatalities or treatment-emergent serious or severe adverse events were reported throughout the *** SOF/DCV combined therapy could be used safely and effectively in the treatment of chronic HCV genotype-4 infection in leukemia/lymphoma treated *** relapses were detected during treatment and throughout the follow up period for either the original malignant disease or the HCV infection.

关键词： Chronic hepatitis C Survivors of childhood cancer Sofosbuvir daclatasvir Efficacy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir

引用

World Journal of Clinical Cases 2015年第12期3卷 1005-1010页

作者： Takayoshi Suga Ken Sato Yuichi Yamazaki Tatsuya Ohyama Norio Horiguchi Satoru Kakizaki Motoyasu Kusano Masanobu Yamada Department of Medicine and Molecular Science Gunma University Graduate School of Medicine Department of Endoscopy and Endoscopic Surgery Gunma University Hospital

A 66-year-old, interferon-ineligible, treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C virus genotype 1b began combination therapy with daclatasvir and asunaprevir. On day 14 of treatment, hepatic reserve and renal function deterioration was observed, while his transaminase levels were normal. Both daclatasvir and asunaprevir were discontinued on day 18 of treatment, because the patient complained of dark urine and a rash on his trunk and four limbs. After discontinuing antiviral therapy, the abnormal laboratory finding and clinical manifestations gradually improved, without recurrence. Our case fulfilled the diagnostic criteria of probable drug reaction with eosinophilia and systemic symptom(DRESS) syndrome. Despite the 18-d treatment, sustained virological response 12 was achieved. Based on the clinical course, we concluded that there was a clear cause-and-effect relationship between the treatment and adverse events. To our knowledge, this patient represents the first case of probable DRESS syndrome that includes concomitant deterioration of hepatic reserve and renal function due to combination therapy with daclatasvir and asunaprevir, regardless of normalization of transaminase levels. Our case suggests that we should pay attention not only to the transaminase levels but also to allergic symptoms associated with organ involvement during combination therapy with daclatasvir and asunaprevir.

关键词： Hepatitis C daclatasvir Renal dysfunction Asunaprevir Hepatic reserve deterioration

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients

引用

World Journal of Hepatology 2017年第11期9卷 544-550页

作者： Kazuo Tarao Katsuaki Tanaka Akito Nozaki Akira Sato Toshiya Ishii Hirokazu Komatsu Takaaki Ikeda Tatsuji Komatsu Shozo Matsushima Kenji Oshige Tarao’s Gastroenterological Clinic Gastroenterological Center Medical Center Yokohama City University Division of Gastroenterology Department of Internal Medicine St. Marianna University Yokohama City Seibu Hospital Department of Gastroenterology Yokohama Municipal Citizen’s Hospital Department of Gastroenterology Yokosuka General Hospital Uwamachi Department of Clinical Research National Hospital Organization Yokohama Medical Center Yokohama National University Center for Health Service Sciences

To survey the efficacy and safety of dual therapy with daclatasvir and asunaprevir in the elderly hepatitis C virus (HCV) patients multicentricity. METHODSInterferon-ineligible/intolerant patients and non-responders to previous pegylated-interferon/ribavirin therapy with chronic HCV genotype 1b infection were enrolled. Child B, C cirrhotic patients were excluded. Patients received oral direct acting antiviral treatment consisting of 60 mg daclatasvir once daily plus 200 mg asunaprevir twice daily for 24 wk. We divided the patients into two groups of 56 elderly patients (≥ 75 years-old) and 141 non-elderly patients (24). In the former, 1.8% experienced viral breakthrough, as compared with 3.5% in the latter (not significant). Adverse events occurred in 55.4% of the former and 56.0% of the latter. In the former, 7 cases (12.5%) were discontinued due to adverse events, and in the latter 9 cases were discontinued (6.4%, not significant). CONCLUSIONDual therapy with daclatasvir and asunaprevir achieved the same high rates of SVR24 in HCV elderly patients without more adverse events than in the non-elderly patients.

关键词： Asunaprevir Chronic hepatitis daclatasvir Dual oral therapy Elderly patients Hepatitis C virus infection Hepatitis C virus Liver cirrhosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and Safety of daclatasvir in Hepatitis C: An Overview

引用

Journal of Clinical and Translational Hepatology 2016年第4期4卷 336-344页

作者： Nesrine Gamal Stefano Gitto Pietro Andreone Department of Medical and Surgical Sciences University of Bologna Bologna Italy

Hepatitis C virus (HCV) infection is a growing public health concern,with 184 million people infected *** the past decade,interferon has been the backbone of HCV treatment,even though it remains far from *** latest development of the new direct antivirals has drastically changed the treatment approach for chronic hepatitis C (CHC).Inhibitors of the HCV NS5A region have garnered remarkable interest among treating physicians,due to their high potency and favourable safety *** particular,treatment with daclatasvir (DCV) has yielded high rates of vriologic response in patients infected with genotype (Gt) 1 and Gt 3,when used in combination with other antivirals of a different class,such as *** few data are available for DCV treatment of the other Gts,the results in patients with Gt 2 and Gt 4 infection appear promising,as do those for unique patient ***5A-resistant viral variants can pre-exist or emerge after treatment failure for the HCV NS5A ***,DCV-resistant viral variants continue to be sensitive to interferon and other classes of antivirals such as NS3/4A and NS5B ***,we aimed to provide an overview of the current knowledge about DCV in the treatment of CHC.

关键词： daclatasvir NS5A inhibitor Hepatitis C Direct antivirals New antiviral therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

daclatasvir联合asunaprevir治疗基因1b型慢性丙型肝炎1例报告

引用

南方医科大学学报 2016年第8期36卷 1163-1164页

作者：皮赛男陈友鹏暨南大学附属第一医院感染科广东广州510630

daclatasvir和asunaprevir作为直接抗病毒药物来联合治疗基因1b型慢性丙型肝炎患者,可获得较高的持续病毒学应答率。目前国内尚无使用该方案治疗基因1b型患者的报道。本文报告1例基因1b型慢性丙型肝炎青年女性患者使用该方案治疗24周,... 详细信息

daclatasvir和asunaprevir作为直接抗病毒药物来联合治疗基因1b型慢性丙型肝炎患者,可获得较高的持续病毒学应答率。目前国内尚无使用该方案治疗基因1b型患者的报道。本文报告1例基因1b型慢性丙型肝炎青年女性患者使用该方案治疗24周,获得持续病毒学应答,最后临床治愈;但出现一过性胆红素升高、轻度血红蛋白下降,波动于100~110 g/L。

关键词： daclatasvir asunaprevir 慢性丙型肝炎基因1b型治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：